Navigation Links
Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results

BELGRADE, Mont., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Bacterin International Holdings, Inc. ("Bacterin" or the "Company") (OTC Bulletin Board: BIHI), a developer of anti-infective coatings for medical applications and revolutionary bone graft material, today reported financial results for its third quarter ended September 30, 2010.  On July 1, 2010, as a result of the reverse merger transaction reported in the Company's Form 8-K dated June 30, 2010, Bacterin began trading as a public entity under the symbol BIHI.OB.  During the third quarter, the Company completed a second and final closing on a private placement funding totaling $9.3 million, materially increased its direct and indirect biologics sales force, launched a marketing and sales initiative into the 6,000 medical facilities covered under the Broadlane® (a general purchasing organization) agreement, and received FDA approval to market its second coatings device (an antimicrobial needleless IV connector).   Subsequent to third quarter end, Bacterin announced within its biologics division the launch of its third scaffold addressing dermal repair and within the company's coatings division a $237,000 grant was awarded from the Federal Government for its antimicrobial orthopedic surgical fixation devices.

Bacterin reported third quarter 2010 revenues of $4.2 million, a 203 percent increase from the prior year's third quarter revenues of $1.4 million and a 31 percent increase compared to revenues of $3.2 million in the second quarter of 2010.  The Company's revenue growth acceleration reflected the impact of the implementation of a direct sales force effort, which commenced in July 2009.  As of September 30, 2010, the Company's sales force totaled 35 biologics sales representatives, which has grown from 21 as of June 30, 2010.   During October 2010, Bacterin further increased its sales force and achieved its 2010 goal of hiring 52 sales representatives.  The Company anticipates continued revenue growth acceleration as both its expanding direct and indirect sales efforts impact the market.  

The Company reported a net loss of $(9.0) million or $(0.26) per basic share for the third quarter of 2010, which included a non cash warrant derivative liability charge of $6.7 million due to the strong appreciation in the stock price to $7.45 during the quarter. This compares to $(1.9) million or $(0.09) per basic share for the third quarter 2009 and a net loss of $(2.0) million or $(0.07) per basic share for the second quarter 2010.  During the final month of third quarter 2010, Bacterin achieved EBITDA breakeven.  The Company expects to be EBITDA profitable for the fourth quarter of 2010 going forward.

For the three months ended September 30, 2010, Bacterin's gross profit on revenue totaled $3.5 million, yielding a gross margin of 83 percent, compared to 30 percent for the three months ended September 30, 2009 and 84 percent for the second quarter of 2010.  The material year over year gross margin increase was due to a one time inventory adjustment of approximately $669,000 which resulted in an increase in cost of tissue sales recorded in the third quarter of 2009.   Given the company's current mix of business, Bacterin expects gross margins over 80 percent for the foreseeable future.

Operating expenses during the third quarter of 2010 totaled $5.6 million, an increase of approximately $3.4 million (159%) over the third quarter of 2009 and an increase of approximately $1.6 million (41%) over the second quarter of 2010.  A significant portion of the expense increase, approximately $2.0 million year-over-year and $636,000 quarter-over-quarter, was attributed to costs associated with the implementation of a direct sales force.  General and administrative costs also increased approximately $672,000 year-over-year and $200,000 quarter-over-quarter due to an increase in salaries and wages and legal, professional fees and insurance expense associated with being a public company.  In addition, stock options/restricted stock compensation expense which consists of non-cash expense associated with granting stock options to employees and restricted stock to consultants increased during the third quarter by $808,000 over the prior year third quarter and by $769,000 as compared to the second quarter 2010, due largely to restricted stock awards to consultants during the third quarter 2010.  While Bacterin anticipates a continued increase in operating expenses going forward, the Company believes it will be able to leverage its corporate expenses and deliver increased profitability as revenues continue to rise.

The Company generated interest expense in the third quarter of $160,000 compared to $136,000 in the third quarter of 2009 and $782,000 in the second quarter of 2010.  The shift in quarterly interest expense is attributed to the creation and subsequent conversion of short term convertible debt instruments.

For the nine months ended September 30, 2010, Bacterin reported revenues of $10.1 million, a 95 percent increase compared to the same period in 2009.  The increase of $4.9 million was largely the result of transitioning the sales model in the second half of 2009 from a distributorship model with a limited direct sales force to a direct sales force model.  Net loss totaled $(12.7) million or $(0.42) per basic share, which included approximately $1.1 million in nonrecurring costs associated with the reverse merger and concurrent capital raise as well as $6.8 million of a non cash warrant derivative liability charge due to the strong rise in the company's stock price since becoming a public traded entity on July 1, 2010.  This net loss is compared to $(2.5) million or $(0.10) per basic share for the same period in 2009.  

At September 30, 2010, the Company reported cash and equivalents balance of $572,000, accounts receivable of $2.6 million and an inventory balance of $7.0 million.
At September 30, 2010 the Company had convertible notes payable of approximately $400,000, a decrease of $1.45 million from the prior second quarter 2010.   As of September 30, 2010, Bacterin had approximately 35.9 million shares of common stock outstanding and fully diluted shares of 48.4 million (inclusive of all options, warrants and convertible debt).

"After multiple years of product development and testing, we began preparing the business to capitalize on our core markets, as well as the active marketing of our product in 2009.  In particular, we diversified our supply of donor tissue, expanded our production capabilities, developed the infrastructure of what we believe will grow into a formidable sales force, refined the message to our market and started gathering proof points on how to scale our revenue in these markets.  During 2010, these efforts have produced sequential increasing record revenue quarters and sustainable gross margins above 80 percent with prospects of future revenue growth acceleration and profitability as we exit this current calendar year.  We anticipate further growth opportunities during 2011 as we begin to market and sell our new dermal scaffold and announce progress on our products that address subchondral bone repair," commented Guy Cook, the Company's President and CEO.Conference Call Details:Date/Time:Monday, November 15, 2010—10:00 a.m. (ET)Telephone Number:888-713-4217International Dial-In Number:617-213-4869Participant Pass code:65563395Internet or www.earnings.comIt is recommended that participants phone-in at least 10 minutes before the call is scheduled to begin. Participants may pre-register for the call at -  Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection. A replay of the conference call in its entirety will be available approximately one hour after its completion by dialing 888-286-8010 (U.S.), 617-801-6888 (International) and entering the pass code 21194807 and on the Internet at

About Bacterin International Holdings, Inc.Bacterin International Holdings, Inc. ("the "Company" or "Bacterin") develops, manufactures and markets biologics products to domestic and international markets.  Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth.  These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing following neurosurgery and cartilage regeneration in knee and other joint surgeries.

Bacterin's Medical Device division develops anti-microbial coatings based upon proprietary coating technologies. Bacterin develops, employs, and licenses bioactive coatings for various medical device applications.  Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination on medical devices' drug delivery, local (as opposed to systemic) pain management, and anti-thrombotic factors for medical device applications.  Headquartered in Belgrade, Montana, Bacterin operates a 32,000 square foot., state-of-the-art, fully compliant and FDA registered facility, equipped with five "Class 100" clean rooms.  For further information please visit

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. These forward-looking statements are based on current expectations or beliefs and include, but are not limited to, statements about the Company's earnings release and its expectations based on the results of third quarter of 2010, including reductions in expenses and increases in revenues due to among other things, the anticipated growth of its sales force. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability and willingness of third-party manufacturers to timely and cost-effectively fulfill orders from the Company; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.


December 31,20102009ASSETS(unaudited)Current Assets:Cash and cash equivalents

54,155Accounts receivable, net of allowance of $122,949 and $81,803, respectively

2,560,6921,314,418Notes receivable - trade

518,905270,565Inventories, net

6,971,7925,000,713Prepaid and other current assets

221,56730,00010,844,8006,669,851Property & equipment, net

3,117,4393,248,096Intangible assets, net

541,417554,268Notes receivable – related party

82,255-Other assets

15,58513,675Total Assets

$14,601,496$  10,485,890LIABILITIES & STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable  

1,749,9381,403,950Accrued liabilities

1,052,972463,630Other current liabilities

315,000-Warrant derivative liability

7,429,96875,231Notes payable

956,9781,126,693Notes payable to stockholders

162,397183,461Current portion of capital lease obligations

35,78085,071Convertible notes payable, net of debt discount

393,834820,787Current portion of long-term debt

1,097,5251,202,574Long-term Liabilities:   Capital lease obligation, less current portion

-27,074   Long-term debt, less current portion

292,800412,545Total Liabilities

13,487,1925,801,016Stockholders' EquityPreferred stock, $.0001 par value; 15,000,000 shares authorized; Common stock, $0.000001 par value; 135,000,000 shares authorized; 35,903,864 Issued shares and 35,900,160 outstanding shares on September 30, 2010 and 28,211,562 Issued shares and 28,152,665 outstanding shares on December 31, 2009

3628Additional paid-in capital

31,538,98722,238,747Treasury stock, 58,897 shares on December 31, 2009 and 3,704 shares on September 30, 2010

(212,036)(76,566)Retained deficit

(30,212,683)(17,477,335)Total Stockholders' Equity

4,601,496$   10,485,890BACTERIN INTERNATIONAL HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)ThreeNineMonths Ended September 30,Months Ended September 30,2010200920102009RevenueTissue sales

$4,045,347$1,356,842$9,936,095$4,995,682Royalties and other

146,63925,975193,424207,554Total Revenue

4,191,9861,382,81710,129,5195,203,236Cost of tissue sales

711,173973,4361,832,9671,631,555Gross Profit

3,480,813409,3818,296,5523,571,681Operating ExpensesGeneral and administrative

2,141,0281,468,9365,741,3153,705,892Sales and marketing


152,994166,964457,156495,218Stock Options/Restricted stock Compensation expense

951,442143,1211,227,871446,960Total Operating Expenses

5,565,9102,145,84812,891,7735,769,066Loss from Operations

(2,085,097)(1,736,467)(4,595,221)(2,197,385)Other Income (Expense)Interest income (expense)

(160,289)(135,715)(680,418)(337,303)Change in warrant derivative liability

(6,731,857)-(6,826,533)-Other income/expense

(65,984)-(633,176)11,298Total Other Income (Expense)

(6,958,130)(135,715)(8,140,127)(326,005)Net Loss Before Benefit(Provision)for Income Taxes

(9,043,227)(1,872,182)(12,735,348)(2,523,390)Benefit (Provision) for Income TaxesCurrent


----Net Loss

$(9,043,227)$(1,872,182)$(12,735,348)$(2,523,390)Net loss per share:Basic

$(0.26)$(0.09)$(0.42)$(0.10)Shares used in the computation:Basic


SOURCE Bacterin International Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin International Completes $3 Million Private Placement
2. Bacterin International Introduces OsteoSelect(R) DBM Putty
3. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
4. Bacterin International Holdings, Inc. Completes Merger and $7.5 Million Raise
5. Bacterin International Holdings, Inc. to Present at the 6th Annual Fall Growth Stock Conference Hosted by Security Research Associates, Inc.
6. Bacterin International to Present at Singular Research 5th Annual Best of the Uncovereds Conference
7. Bacterin International Holdings, Inc. Schedules Conference Call to Present Third Quarter 2010 Financial Results
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
Breaking Medicine News(10 mins):